About
Novavax, Inc. develops protein-based nanoparticle vaccines enhanced with its proprietary Matrix-M adjuvant to generate strong and durable immune responses against infectious diseases.
Explore Novavax, Inc's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.